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Abstract
Long-chain triglycerides inhibit gastric acid secretion, but the effect of medium-chain triglycerides in humans is unknown. We 
compared the effects of intraduodenally perfused saline, medium-chain and long-chain triglycerides on gastrin-stimulated gastric acid 
secretion and cholecystokinin release. Eight healthy male volunteers participated in this study. Gastrin-stimulated gastric acid output was 
9.4 ± 1.1 mmol/30 min during saline perfusion. It was suppressed by medium-chain triglycerides by 43 ± 9% ( P  = 0.04 vs. saline) and 
by long-chain triglycerides by 74 ±  6% ( P  — 0.0003 vs. saline). Thus medium-chain triglycerides inhibited gastrin-stimulated gastric acid 
secretion but less so than long-chain triglycerides. When compared to saline perfusion (73 ± 6 pM X 30 min) integrated plasma 
cholecystokinin concentrations were significantly elevated by long-chain triglycerides (96 ±5 pM X 30 min, P < 0,004) but not by 
medium-chain triglycerides perfusion (65 ±  7 pM X 30 min). We also investigated the role of cholecystokinin infusion on gastrin 
stimulated gastric acid secretion. Higher concentrations (191.4 ± 4,5 pM X 30 min) of CCK than released in the long-chain triglycerides 
perfusion experiment, did not suppress gastric acid secretion. Thus, circulating cholecystokinin appears not responsible for the inhibition 
of gastrin-stimulated gastric acid secretion by dietary fat.
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1. Introduction
The regulation of gastric acid secretion is important, 
since gastric acid is involved in the pathogenesis of fre­
quently occurring diseases, like reflux oesophagitis and 
peptic ulcers. The presence of nutrients in the small intes­
tine inhibits gastric acid secretion in many species, includ­
ing humans [1-4], The term ‘enterogastrone* has been 
introduced [5] to describe the undefined intestinal factors) 
responsible for this effect. In humans cholecystokinin 
(CCK) appears to be involved [6,7], but other enterohor- 
mones such as secretin [8], somatostatin [9], pancreatic 
polypeptide, peptide YY [10], gastric inhibitory polypep­
tide [11] and neurotensin [12] have also been put forward. 
We have earlier demonstrated that long-chain triglycerides 
but not medium-chain triglycerides (MCT) are potent stim­
uli for the release of CCK and for gallbladder contraction
in humans [13]. We question now whether long-chain and 
medium-chain triglycerides also differ in their effects on 
gastrin stimulated gastric acid secretion and whether CCK, 
infused to plasma concentrations somewhat higher than 
found during perfusion of the duodenum with long-chain 
triglycerides, was able to inhibit gastrin-stimulated gastric 
acid secretion.
2. Materials and methods
* Corresponding author. Tel.: (31-24) 361-4760; Fax: (31-24) 354-0103.
2,1. Subjects
Eight healthy male volunteers (20-25 years) partici­
pated in the studies. Body mass indexes ranged from 22 to 
29 kg/m2. None of the subjects had a history of gastro-in­
testinal diseases or surgery and none was taking any 
medication. One volunteer smoked cigarettes. The study 
protocol was approved by the Medical Ethical Committee 
of the University Hospital Nijmegen, and written informed 
consent was obtained from each volunteer.
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2.2. Materials
Synthetic non-sulphated gastrin-17 for intravenous infu­
sion was purchased from Cambridge Research Biochemi­
cals (UK). It was dissolved under aseptic conditions in 
saline containing 2% human serum albumin and stored at 
— 20°C. Highly purified porcine cholecystokinin-33 for 
intravenous infusion was purchased from Ferring (Malmo, 
Sweden). Synthetic human CCK33 for radioimmunoassay 
was purchased from Peninsula Laboratories (St. Helens, 
UK); radioiodinated porcine PP ( 125I-PPP) from Novo 
Nordisk AS (Bagsvaerd, Denmark). MCT (Ceres-MCT-di- 
etary oil) containing 56% octanoic acid (C8) and 43% 
decanoic acid (C 10), was from Bakker (Etten-Leur, The 
Netherlands). LCT (corn oil), containing 10% palmitic 
acid (C 16:0), 27% oleic acid (C l8:1) and 57% linoleic acid 
(C]8:2) was from Genfarma (Maarsen, The Netherlands).
23. Experimental design
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Fig. 1. Design for the three experiments performed in random order in 
eight subjects and for the fourth experiment in six subjects. In all 
experiments the stomach was continuously perfused with a saline solution 
containing 3 mg/1 phenol red at a rate of 8 ml/min. Each experiment 
consisted of the following periods: (a) a basal period of 60 min; (b) an 
intravenous infusion period of gastrin at a dose of 10 pmol/kg per h for 
60 min; and (c) an intraduodenal perlusion/infusion period of equimolar 
amounts (40 mmol/h) of long-ehain triglycerides, medium-chain triglyc­
erides, or saline (60 ml) or intravenous cholecystokinin (1.1 ±0.2 
pmol/kg per h) for 90 min. Blood sampling lor the measurement of 
plasma gastrin and cholecystokinin is indicated by triangles. Gastric juice 
was collected continuously and sampled at 15-min intervals (*).
MCT, LCT or saline was perfused intraduodenally in 
random order on different days separated by at least 1 
week. In a fourth experiment, six of the 8 volunteers were 
also given intravenous CCK. After an overnight fast, the 
volunteers presented at the gastrointestinal research labo­
ratory at 7:30 a.m. A single-lumen polyvinyl perfusion 
catheter was placed into the proximal duodenum under 
fluoroscopic control (in the first three experiments) and a 
polyvinyl gastric drainage tube into the stomach together 
with a small-bore polyethylene perfusion catheter inserted 
into one of the three side holes of the gastric drainage tube 
(in all four experiments). The position of this tube was 
checked by the water recovery method [14]. Subsequently, 
the small-bore gastric polyethylene perfusion tube was 
pulled back about 10 cm, to release it from the drainage 
tube. The stomach was emptied and subsequently perfused
1). During the final 1.5 h of the experiments either saline 
(60 ml), or equimolar amounts (60 mmol/60 ml) of MCT 
or LCT were perfused intraduodenally at a rate of 40 
ml/h. In the fourth experiment cholecystokinin was in­
fused intravenously during the final 1.5 h of the experi­
ment in a dose of LI ± 0.2 pmol/kg per h as measured 
from the tip of the infusion line. No intraduodenal tube 
was inserted in this experiment. Immediately after the 
experiments, blood samples were centrifuged for 15 min at 
4000 rpm and plasma was stored at ~20°C. The volume 
and pH of each 15-min gastric juice sample was recorded, 
and the H+ concentration was determined by titration to 
pH 7.0 with 0.1 M NaOH. Subsequently, gastric samples 
were filtrated and alkalized with 2.5 M NaOH and the
continuously through the small bore polyethylene perfu- concentration of phenol red was measured speclrophoto-
sion tube with a saline solution containing 3 mg/1 of metrically at 560 nm Recovery of gastric juice was calcu-
phenol red at a rate of 120 ml/15 min. Gastric contents lated by the equation: (VA X ABSa ) / ( V v X ABS,,\ in
ft a  ft «  - k « m *
were aspirated continuously during the experiments using 
a suction pump that provided intermittent negative pres­
sure. The gastric aspirates were collected in 15 min por­
tions and kept on ice. Indwelling intravenous catheters
which VA represents the aspirated volume, ABSa ihe phe­
nol red absorption of the aspirated volume, l'(> the per­
fused volume and ABS,, the phenol red absorption of the 
perfused volume, each per 15-min period. The amount of
were placed into the left and right forearm. The catheters acid secreted (m mol/15 min) was calculated as follows: 
were kept patent by a heparin-saline solution. One catheter (acid concentration measured) X  /recovery, 
was used for the collection of blood samples and the other Gastrin, CCK and PP concentrations in" plasma were
for the infusion of non-sulphated gastrin-17 at a dose of 10 measured by sensitive and specific radioimmunoassays as 
pmol/kg per h. This dose produces plasma gastrin concen- previously described [16-19]. 
trations similar to those found after a meal [15]. Blood 
samples were taken every 30 min during the 1 h basal 
period and every 15 min during the subsequent gastrin 
infusion period. Blood samples were collected into ice- 
chilled 10 ml glass tubes containing 15 mg EDTA.
Four 15-min gastric samples were collected under un-
2.4. Data analysis
Results are expressed as mean ± SFM unless stated
otherwise.
Basal gastric acid output is defined as the sum of the 
stimulated conditions. Subsequently, the intravenous gas- last two 15-min portions obtained under unstinuilated con-
trin-17 infusion was started and continued for 2.5 h (Fig. ditions. Gaslrin-sti mu lated gastric acid output is defined as
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the sum of the last two 15-min portions obtained during 
the first hour of gastrin-17 infusion. The percentage of 
inhibition by saline, MCT, LCT or CCK on gastric acid 
secretion was calculated as follows:
(¿4 5  +  t 6Q )  —  (  t f t i ?15o)
X 100%
■ f io
in which t45 + r60 are the amounts of gastric acid produced 
during the final 30 min before fat perfusion and f135 + tl50 
are those produced during the final 30 min of the fat 
perfusion period (Fig. 1). Integrated plasma CCK and PP 
concentrations for the last 30 min of each experimental 
period are calculated by using the trapezoidal rule as area 
under the serum concentration vs. time curves.
Statistical analysis was performed by two-way ANOVA 
and the Student’s r-test for paired results. All P-values are
3. Results
3.1. Plasma gastrin concentrations
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Infusion of gastrin increased plasma gastrin concentra­
tions from basal concentrations of 26 ± 4 to 50 ± 6 pM in 
the saline experiment, from 20 ± 3 to 46 ± 4 pM in the 
MCT experiment, from 25 ± 4 to 55 ± 5 pM in the LCT 
and from 20 + 3 to 46 ± 4 pM in the CCK-infusion experi­
ment (means ± SEM). Duodenal perfusion of saline, MCT 
or LCT or intravenous infusion of CCK did not signifi­
cantly affect these plasma gastrin concentrations.
32. Plasma cholecystokinin and pancreatic polypeptide
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Fig, 2. Mean gastric acid output ±SEM in eight volunteers under basal 
conditions and during intravenous infusion of gastrin (10 pmol/kg per h), 
subsequently combined with intraduodenal administered long-chain 
triglycerides (40 mmol/h; a ), medium-chain triglycerides (40 mmol/h; 
□ ) or saline (60 ml; • ) .
significant increase in plasma pancreatic polypeptide con 
centrations (Table 3).
concentrations 3.3, Gastric acid secretion
As shown in Tables 1 and 2, saline perfusion had no 
effect on plasma CCK. Perfusion of MCT had no effect 
either. Perfusion of LCT stimulated integrated plasma 
CCK concentrations by 25% (P = 0.004) vs. saline (Table 
1). In experiment four, integrated plasma CCK concentra­
tions were more than doubled during cholecystokinin infu­
sion (Table 2). Cholecystokinin infusion resulted in a
Infusion of gastrin markedly stimulated basal gastric 
acid output (Tables 4 and 5), Intraduodenal perfusion of 
MCT suppressed gastrin stimulated gastric acid secretion 
by 43% compared to saline; LCT resulted in a more 
marked suppression of 74% (Table 4 and Fig. 2). In the 
CCK-infusion experiment, absolute levels of acid output 
were somewhat lower before CCK infusion than before
Table 1
Effect of LCT and MCT on plasma cholecystokinin concentrations 
Treatment Plasma cholecystokinin
Basal Gastrin Gastrin + Fat or Saline Change
(pM X 30 min) (pM X 30 min) (pM X  30 min) (pM X 30 min)
Saline 84.2 ±5.5 71.8 ±6.1 73.1 ±6.1 1.3 ±5.3
MCT 80.4 ±4.1 70.9 ±6.1 64.6 ± 6.8 -4.8 ±4.2
LCT 92.4 ±4.4 76.7 ± 4.8 95.7 ±5.2 19.0 ±4.1 a*h
Mean integrated plasma cholecystokinin concentrations ± SEM before intravenous gastrin infusion (basal), during intravenous gastrin infusion, and during 
intraduodenal perfusion of long-chain triglycerides (LCT), medium-chain triglycerides (MCT) or saline in combination with intravenous gastrin infusion in 
eight subjects. Changes are the effect of fat perfusion during gastrin infusion relative to gastrin infusion alone.
n Compared to saline, P =  0.0039. 
b Compared to MCT, P = 0.0042.
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Table 2
Cholecystokinin concentrations after intravenous cholecystokinin infusion
Treatment Plasma cholecystokinin
Basal
(pM X 30 min)
Gastrin
(pM X 30 min)
Gastrin + CCK or Saline 
(pM X 30 min)
Change
(pM x 30 min)
Saline
CCK
86.0 ±7.3 
81.3 ±6.2
74.9 ±7.7 
82.6 ± 12.8
84.8 ± 8.1 
191.4 ±4.5
l>.9 ± 3.f t
10H.H ± 10.5
integrated plasma cholecystokinin concentrations ± SEM before iniravenous gastrin ¡illusion (teal), during intravenous gastrin infusion, and during 
:nous infusion of saline or cholecystokinin in six subjects. Iniravenous gastrin infusion was continued during saline nr CCK infusion. Changes are
Mean
intravenous infusion of saline or cholecystokinin in six subject, 
the effect of CCK infusion combined with gastrin inlusion relative to gastrin infusion alone,
saline (Fig. 3; ¿=30  to / = 60 min). However, gastric acid 
secretion was not inhibited by CCK relative to control 
(Table 5 and Fig. 3; 120-150 min vs. 30-60 min).
4. Discussion
Our first objective was to determine whether long-chain 
and medium-chain triglycerides have different effects on 
gastrin-stimulated gastric acid secretion, since we have 
earlier demonstrated that long-chain triglycerides but not 
medium-chain triglycerides are potent stimuli for the re­
lease of CCK and for gallbladder contraction in humans 
[13]. We have found that intraduodenal perfusion of fat 
mainly composed of long-chain triglycerides as well as fat 
composed of medium-chain triglycerides suppressed gas­
trin-stimulated gastric acid secretion in humans, MCT 
being less potent than LCT,
Our finding that fat composed of medium-chain triglyc­
erides did not evoke an increase in the release of cholecys­
tokinin, in contrast to fat mainly composed of long-chain 
triglycerides agrees with previous studies [13,20,21],
Our second objective was to examine the role of CCK 
in the inhibition of gastrin-stimulated gastric acid secre- amounts of fatty acids released by hydrolysis [27-29],
The situation in humans is in contrast to what has been 
found in rats. In rats medium-chain triglycerides evoke a 
greater CCK-release than triglycerides with longer chain 
lengths as measured by the same radioimmunoassay [22]. 
The reason for this discrepancy is not obvious, but it 
suggests important species differences with respect to 
plasma CCK release [23],
In previous studies it was found that isocalorie amounts 
of fat, protein, and carbohydrates similarly inhibit gastric 
emptying [24,25], The different inhibitory effect of 
medium-chain triglycerides and long-chain triglycerides on 
gastric acid secretion might also be explained by differ­
ences in caloric load between the long-chain and medium- 
chain triglycerides, vSo far, the effect of caloric load of 
different nutrients on gastric acid secretion has only been 
studied in calves [26] where it was found that energy 
contents did not affect gastric acid secretion. Whether the 
effect of nutrients on iiastric acid secretion in humans is
dependent on the molar or caloric load of fats remains to 
be established. In the present study, we have chosen to 
compare medium-chain and long-chain triglycerides on a 
molar base, since previous studies suggest that the CCK 
stimulating capacity of nutrients is related to the molar
tion. We showed in the present study that circulating CCK 
plays no role in MCT-induced inhibition of gastrin-stimu­
lated gastric acid secretion and also that infusion of CCK 
did not inhibit gastrin-stimulated gastric acid secretion.
Our results suggest that the chain-length of the con-
We have tested the enterogastronc effect of fat on 
gastrin-stimulated rather than on meal-stimulated gastric 
acid secretion to avoid difficulties encountered in the 
sampling of gastric juice after a meal, For the same reason 
we have administered fat intraduodenally. Despite the use
stituent fatty acids is not only important for the release of of gastrin instead of food and the duodenal instead of oral
CCK, but also for the enterogastrone effect of fat. administration of fat, we believe that our findings are of
Table 3
Pancreatic polypeptide concentrations after intravenous cholecystokinin infusion
Treatment Plasma pancreatic polypeptide
Basal
(pM X 30 min)
Gastrin 
(pM X 30 min)
Saline
CCK
465 ±21 
455 ± 26
434 ± 24 
444 ±61
Gastrin 4 CCK or Saline 
(pM x 30 min)
nnituv
(pM * 30 min)
470 ± 47 
75*) ± 15l)
Mean integrated plasma pancreatic polypeptide concentrations ± SEM before intravenous gastrin infusion ihasall. during in.rau-n.Hi> g;
during intravenous infusion ot saline or cholecystokinin in six subjects. Iniravenous gastrin infusion was comimu-d durum silmc or CCK 
are the effect of CCK infusion combined with gastrin infusion relative to gastrin infusion alone
* P = 0.048.
iMrin infusion, and 
inlusion. Changes
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Table 4
Treatment Gastric acid output 
Basal
(mmol/30 min)
Gastrin
(mmol/30 min)
Saline
MCT
LCT
2.1 ± 1.24 
1.7+ 1.1 
2.6+ 1.5
10.8 ± 3.7 
12.0 + 2.9 
10.6 + 4.8
Gastrin + Fat or Saline 
(mmol/30 min)
9.4 ±3.1
6.5 + 2.6 
2.3 ±0.9
Change 
(%)
9.4 + 6.5 
-43.0 ±9.1 a
-74.3 ±6.2 b'c
Mean gastric acid output ± SEM before gastrin infusion (basal), during gastrin 17-1 infusion and during (A) intraduodenal perfusion of long-chain 
triglycerides (LCT), mcdium-chain triglycerides (MCT) or saline in eight subjects. Intravenous gastrin infusion was continued during the intraduodenal 
perfusion of fat or saline. Changes are the effect of fat perfusion during gastrin infusion relative to gastrin infusion alone. 
a Compared to saline, P = 0.0426.
b Compared to saline, P — 0.0003. 
c Compared to MCT, P = 0.0499.
physiological relevance. Firstly, infusion of gastrin re­
sulted in plasma gastrin concentrations in the same range 
as observed after a meal [15]. Secondly, gastrins are the 
major factor responsible for postprandial gastric acid secre­
tion [30]. Thirdly, gastrin-17 is the major molecular form 
of gastrins released in response to a meal [31], whereas 
non-sulphated gastrin-17 is equipotent to sulphated gastrin- 
17 in stimulating gastric acid secretion [32], and finally, 
we have perfused fat into the duodenum at a rate that was 
comparable to the gastric emptying rate of fat after a meal
[33].
The mechanisms through which nutrients inhibit gastric 
acid secretion when they enter the small intestine, the so 
called enterogastrone effect, are not clear. Several possibil­
ities have been suggested [7,9-12,34]. Of old, one of the 
most important enterogastrone candidates is CCK [7], In 
previous studies, infusion of high, probably supraphysio- 
logical, doses of CCK inhibited gastric acid secretion [35], 
Recent studies with CCK receptor antagonists also support 
an inhibitory effect of endogenous CCK on gastric acid 
secretion, since specific type A CCK-receptor antagonists 
augmented basal as well as stimulated gastric acid output 
[36-41]. However, in the present study infusion of CCK 
did not inhibit gastric acid secretion, and medium chain 
triglycerides were able to inhibit gastric acid secretion 
without concomitant release of CCK. Therefore, MCT-in- 
duced inhibition of gastric acid secretion acts via another 
mechanism. It might be that CCK has an additive effect in 
case of LCT-induced inhibition of gastric acid secretion. 
We have investigated this possibility in two subjects by
Table 5
Effect of CCK infusion on gastrin-stimulated gastric acid secretion
Treatment Gastric acid output 
Basal
(mmol/30 min)
Gastrin
(mmol/30 min)
Saline
CCK
2.5 + 0.9 
2.8 ± 0.9
10.8 ±0.6 
8.6 ± 1.5
combining intraduodenal perfusion of MCT with intra­
venous infusion of CCK. However, the inhibition of gas­
trin-stimulated gastric acid secretion in these 2 subjects 
was comparable to the effect found during intraduodenal 
perfusion of MCT without CCK infusion (data not shown). 
Therefore the present findings suggest that circulating 
CCK is not responsible for the enterogastrone effect of 
MCT, since MCT did not stimulate CCK release into the 
circulation, Furthermore, it is not likely that the more 
potent inhibitory effect of LCT on gastrin stimulated gas­
tric acid secretion when compared to MCT is a result of 
the ability of LCT to release CCK.
Absence of suppression of gastric acid secretion by 
CCK-33 infusion in the present study agrees with the 
observation that intravenous infusion of CCK-8, inducing 
plasma CCK increments within the physiological range, 
did not significantly alter gastrin stimulated gastric acid 
secretion [42]. Absence of acid suppression by CCK in our 
study was not related to lack of biological activity of CCK, 
since CCK infusion markedly stimulated the release of 
pancreatic polypeptide [43-45].
Although our data are in contrast with a role of CCK as 
an enterogastrone, it can not be excluded that CCK acts 
locally as a neurotransmitter or neuromodulator to inhibit 
gastric acid secretion, since specific cholecystokinin recep­
tor antagonists augment gastric acid secretion in previous 
experiments [36-41].
Our finding that circulating CCK does not inhibit gas­
trin-stimulated gastric acid secretion, does not exclude that 
other peptides might be involved in the inhibition of
Gastrin + CCK or saline 
(mmol/30 min)
Change
a
'0
8.9 ± 0.5 
6.9+ 1.1
-16.7 ±4.3 
- 17.9 ± 6.7
Mean gastric acid output ± SEM before gastrin infusion (basal), during gastrin 17-1 infusion and during intravenous infusion of cholecystokinin (CCK) or 
saline in six subjects. Intravenous gastrin infusion was continued during the intravenous infusion of cholecystokinin or saline. Changes are the effect of
CCK infusion combined with gastrin infusion relative to gastrin infusion alone.
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Treatment Gastric acid output
Table 4
Basal Gastrin
(mmol/30 min) (mmol/30 min) (mmol/30 rain)
Gastrin + Fat or Saline Change
(%)
Saline 2.1 + 1.24 10.8 + 3.7 9.4 ±31
MCT 1.7+1.1 12.0 ±2.9 6^ 5 + 2*6
9,4 + 6.5 
-43.0 ± 9.1a
LCT ________________2.6 ^  ^ ____________________10.6 + 4.8 2.3 ± 0.9 —74.3 ± 6.2 b,c
Mean gastric acid output ± SEM before gastrin infusion (basal), during gastrin 17-1 infusion and during (A) intraduodenal perfusion of long-chain 
triglycerides (LCT), medium-cham triglycerides (MCT) or saline in eight subjects. Intravenous gastrin infusion was continued during the intraduodenal 
perfusion of fat or saline. Changes are the effect of fat perfusion during gastrin infusion relative to gastrin infusion alone. 
a Compared to saline, P - 0.0426.
b Compared to saline, P = 0.0003, 
c Compared to MCT, P = 0.0499.
physiological relevance. Firstly, infusion of gastrin re­
sulted in plasma gastrin concentrations in the same range 
as observed after a meal [15]. Secondly, gastrins are the 
major factor responsible for postprandial gastric acid secre­
tion [30]. Thirdly, gastrin-17 is the major molecular form 
of gastrins released in response to a meal [31], whereas 
non-sulphated gastrin-17 is equipotent to sulphated gastrin-
17 in stimulating gastric acid secretion [32], and finally, 
we have perfused fat into the duodenum at a rate that was 
comparable to the gastric emptying rate of fat after a meal 
[33].
The mechanisms through which nutrients inhibit gastric 
acid secretion when they enter the small intestine, the so 
called enterogastrone effect, are not clear. Several possibil­
ities have been suggested [7,9-12,34], Of old, one of the 
most important enterogastrone candidates is CCK [7], In 
previous studies, infusion of high, probably supraphysio- 
logical, doses of CCK inhibited gastric acid secretion [35]. 
Recent studies with CCK receptor antagonists also support 
an inhibitory effect of endogenous CCK on gastric acid 
secretion, since specific type A CCK-receptor antagonists 
augmented basal as well as stimulated gastric acid output 
[36-41]. However, in the present study infusion of CCK 
did not inhibit gastric acid secretion, and medium chain 
triglycerides were able to inhibit gastric acid secretion 
without concomitant release of CCK, Therefore, MCT-in- 
duced inhibition of gastric acid secretion acts via another 
mechanism. It might be that CCK has an additive effect in 
case of LCT-induced inhibition of gastric acid secretion. 
We have investigated this possibility in two subjects by
combining intraduodenal perfusion of MCT with intra­
venous infusion of CCK. However, the inhibition of gas­
trin-stimulated gastric acid secretion in these 2 subjects 
was comparable to the effect found during intraduodenal 
perfusion of MCT without CCK infusion (data not shown). 
Therefore the present findings suggest that circulating 
CCK is not responsible for the enterogastrone effect of 
MCT, since MCT did not stimulate CCK release into the 
circulation. Furthermore, it is not likely that the more 
potent inhibitory effect of LCT on gastrin stimulated gas­
tric acid secretion when compared to MCT is a result of 
the ability of LCT to release CCK.
Absence of suppression of gastric acid secretion by 
CCK-33 infusion in the present study agrees with the 
observation that intravenous infusion of CCK-8, inducing 
plasma CCK increments within the physiological range, 
did not significantly alter gastrin stimulated gastric acid 
secretion [42]. Absence of acid suppression by CCK in our 
study was not related to lack of biological activity of CCK, 
since CCK infusion markedly stimulated the release of 
pancreatic polypeptide [43-45].
Although our data are in contrast with a role of CCK as 
an enterogastrone, it can not be excluded that CCK acts 
locally as a neurotransmitter or neuromodulator to inhibit 
gastric acid secretion, since specific cholecystokinin recep­
tor antagonists augment gastric acid secretion in previous 
experiments [36-41].
Our finding that circulating CCK does not inhibit gas­
trin-stimulated gastric acid secretion, does not exclude that 
other peptides might be involved in the inhibition of
Table 5
Effect of CCK infusion on gastrin-stimulated gastric acid secretion
Treatment Gastric acid output 
Basal
(mmol/30 min)
Saline
CCK
2.5 + 0.9 
2.8 ± 0.9
Gastrin
(mmol/30 min)
10.8 ± 0.6 
8.6 + 1.5
Gastrin + CCK or saline 
(mmol/30 min)
8.9 ± 0.5 
6.9+ 1.1
Change 
(%)
— 16.7 ± 4.3 
-17.9+6.7
Mean gastric acid output ± SEM before gastrin infusion (basal), during gastrin 17-1 infusion and during intravenous infusion of cholecystokinin (CCK) or 
saline in six subjects. Intravenous gastrin infusion was continued during the intravenous infusion of cholecystokinin or saline. Changes are the effect of
CCK infusion combined with gastrin infusion relative to gastrin intusion alone.
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Fig. 3. Mean gastric acid output±SEM in six volunteers under basal 
conditions and during intravenous infusion of gastrin (10 pmol/kg per h), 
subsequently combined with intraduodenal administered saline (60 ml; 
) or intravenously administered cholecystokinin (1.1 ±0,2 pmol/kg per
h; O).
gastrin-stimulated gastric acid secretion by long-chain and 
medium-chain triglycerides. Possible candidates include 
neurotensin, peptide YY, somatostatin, secretin, and gas­
tric inhibitory peptide. Neurotensin is a hormone that 
might inhibit gastric acid secretion. It is released in re­
sponse to fat in the intestine and requires vagal integrity 
for full activity [46]. However, it has been shown that the 
concentrations of neurotensin released by fat are insuffi­
cient to account for the inhibition of gastric acid secretion 
caused by fat ingestion [12].
Somatostatin is established as an important inhibitor of 
several gastro-intestinal functions, including gastric acid 
secretion [47-53]. It is well known that fat is a stimulant 
for somatostatin release [54] but whether medium-chain 
triglycerides are also able to stimulate the release of 
somatostatin is presently unknown. Secretin has also been 
shown to be an inhibitor of gastric acid secretion in dogs 
[8,55], as well as in humans [56] although it seems less 
potent in humans [57].
The only hormone besides CCK and PP which is known 
to be released differently by long-chain and medium-chain 
triglycerides is gastric inhibitory polypeptide. Gastric in­
hibitory peptide is released more potently by long-chain 
than by medium-chain triglycerides in dogs [58] whereas 
in humans it was found to be released by long-chain 
triglycerides but not by medium-chain triglycerides [59]. In 
dogs gastric inhibitory peptide seems to be an important
enterogastrone [60], but in humans its inhibitory potency is 
relatively weak [60,61] and it cannot fully account for the 
inhibition of gastric acid secretion by fat. The best candi­
date to explain the enterogastrone effect of fat is PYY. 
Circulating concentrations of peptide YY released after fat 
ingestion have been shown to be nearly sufficient to 
account for acid inhibition in dog [62] and man [63], In 
addition, it has been shown in rats that PYY can inhibit 
pentagaslrin stimulated gastric acid secretion [64]. But, 
whether MCT has different effects on PYY release than 
LCT remains to be established. However, it is more likely 
to suggest that no single peptide accounts for the full 
enterogastrone effects of fat in the intestine but that combi­
nations of peptides exert a cumulative inhibitory effect as 
shown in humans for secretin and PYY [65],
In conclusion, the present study demonstrated that the 
enterogastrone effect of fat is dependent on the chain-length 
of fatty acids, and that the enterogastrone effect of MCT is 
not explained by the release of CCK into the circulation. 
Furthermore, exogenous CCK in physiological concentra­
tions did not inhibit gastrin stimulated gastric acid secre­
tion. Our findings thus cast doubt on the enterogastrone 
role of CCK, especially regarding dietary fat.
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